Viatris (VTRS) has agreed to acquire Pacira BioSciences (PCRX) for $1.65 billion in cash at $36.50 per share, expected to close by end of 2026. The acquisition adds two marketed pain therapies (Exparel and Zilretta) generating $350.5 million in H1 2026 sales, plus a mid-stage gene therapy candidate (PCRX-201) for knee osteoarthritis. The deal is expected to be immediately accretive to Viatris' financial metrics and strengthen its non-opioid pain management portfolio.

Pacira BioSciences surged 44% after announcing its acquisition by Viatris for $36.50 per share, valuing the company at approximately $1.65 billion. The deal represents a 45% premium to the previous closing price and is expected to close by end of 2026. Viatris plans to leverage Pacira's non-opioid pain management products, including Exparel and Zilretta, to strengthen its innovative medicines business.

A comparison of two Medical Services sector stocks, Viatris (VTRS) and Avantor (AVTR), both holding a Zacks Rank #2 (Buy) rating. Based on valuation metrics including forward P/E ratio (7.01 vs 19.51), PEG ratio (1.92 vs 11.93), and P/B ratio (1.44 vs 1.9), Viatris emerges as the superior value opportunity with a Value grade of A compared to Avantor's C grade.

Viatris (VTRS) is presented as an attractive value investment opportunity, holding a Zacks Rank #2 (Buy) rating with an 'A' Value grade. The stock demonstrates undervaluation across multiple metrics including a P/B ratio of 0.75 (below industry average of 2.17), P/S ratio of 1.37 (below industry average of 1.54), and P/CF ratio of 5.21 (significantly below industry average of 11.92), suggesting solid cash flow and earnings outlook.

Zacks Premium offers investment research tools including the Zacks Rank and Style Scores to help investors identify stocks with strong performance potential. The Zacks Rank #1 stocks have averaged +23.86% annual returns since 1988, more than double the S&P 500. The article highlights Viatris (VTRS) as a stock to watch with a #3 Hold rank and VGM Score of A, noting recent upward earnings estimate revisions and positive momentum.

The WisdomTree U.S. MidCap Dividend ETF (DON) is a smart beta ETF offering exposure to mid-cap dividend-paying stocks with a 0.38% expense ratio and 2.41% dividend yield. With $3.77 billion in assets and 295 holdings, it has delivered 6.93% returns year-to-date with medium risk (beta 0.86). However, cheaper alternatives like Vanguard's VOE (0.05% expense ratio) and iShares' IWS (0.23% expense ratio) offer lower-cost options for similar market exposure.

Recent economic data shows PCE inflation came in softer than expected while Q2 GDP exceeded expectations. Market attention is now focused on the upcoming Friday employment report. Viatris (VTRS) is highlighted as a stock to watch with a Hold rating and attractive valuation metrics.

The generic drug industry shows mixed but resilient performance with companies focusing on operational efficiency and portfolio optimization. Three standout stocks—Amphastar Pharmaceuticals, Sandoz, and Viatris—are well-positioned to capitalize on industry evolution through new product launches, biosimilar expansion, and complex generics development. However, the industry faces persistent pricing pressure and competition, with the Zacks Medical-Generic Drugs industry ranked #160 out of 247 industries.

The generic drug industry is experiencing a mixed but resilient operating environment with pricing pressures offset by healthy underlying demand and new product launches. Three companies—Amphastar Pharmaceuticals, Sandoz, and Viatris—are well-positioned to capitalize on industry evolution through biosimilar expansion, complex generics development, and operational efficiency improvements. The industry currently trades at a valuation discount compared to broader market indices.

Novartis and Teva represent different pharmaceutical strategies: Novartis is a stable innovator with high margins and strong cash flow, while Teva is executing a turnaround from generics to biosimilars with improving profitability but higher debt. Despite Novartis's superior financial metrics, the article recommends Teva for long-term investors due to its more attractive valuation ratios and strong drug pipeline expected to drive growth in 2027.

Eli Lilly and Teva Pharmaceutical represent two different pharmaceutical strategies: Eli Lilly dominates the high-growth GLP-1 market with blockbuster drugs like Mounjaro and Zepbound, posting 44% revenue growth and trading at a 33x forward P/E. Teva operates in generics and biosimilars with lower valuations (16.4x forward P/E) but faces declining sales projections for 2026 and significant debt challenges. The article recommends Eli Lilly as the better buy despite premium valuation due to its continued GLP-1 growth momentum.

The global tacrolimus market is projected to grow from USD 7.3 billion in 2025 to USD 12.7 billion by 2035 at a CAGR of 5.6%, driven by rising organ transplant procedures and increasing autoimmune disease prevalence. Injectable formulations and hospital settings dominate the market, with North America accounting for 40.4% of the market share. Key players are investing in R&D for improved formulations and expanding into emerging markets.